Evidence map›Paper›PMID 37836712›Full record

ArticleMolecules (Basel, Switzerland)2023

Formation of 5-Aminomethyl-2,3-dihydropyridine-4(1

Werner Seebacher, Michael Hoffelner, Ferdinand Belaj, Teresa Pirker, Muaaz Alajlani, Rudolf Bauer, Eva-Maria Pferschy-Wenzig, Robert Saf, Robert Weis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Werner SeebacherPharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstrasse 1, 8010 Graz, Austria.ORCID 0000-0002-5673-0470
Michael HoffelnerPharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstrasse 1, 8010 Graz, Austria.
Ferdinand BelajInstitute of Chemistry, University of Graz, Schubertstrasse 1, 8010 Graz, Austria.ORCID 0000-0001-9749-2109
Teresa PirkerPharmacognosy, Institute for Pharmaceutical Sciences, University of Graz, Beethovenstrasse 8, 8010 Graz, Austria.
Muaaz AlajlaniFaculty of Pharmacy, Al-Sham Private University, 011 Damascus, Syria.ORCID 0000-0001-9087-6863
Rudolf BauerPharmacognosy, Institute for Pharmaceutical Sciences, University of Graz, Beethovenstrasse 8, 8010 Graz, Austria.ORCID 0000-0002-0057-5547
Eva-Maria Pferschy-WenzigPharmacognosy, Institute for Pharmaceutical Sciences, University of Graz, Beethovenstrasse 8, 8010 Graz, Austria.ORCID 0000-0001-8327-0732
Robert SafInstitute for Chemistry and Technology of Materials (ICTM), Graz University of Technology, Stremayrgasse 9, 8010 Graz, Austria.
Robert WeisPharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Schubertstrasse 1, 8010 Graz, Austria.ORCID 0000-0002-7174-6673

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Various 4-aminotetrahydropyridinylidene salts were treated with aldehydes in an alkaline medium. Their conversion to 5-substituted β-hydroxyketones in a one-step reaction succeeded only with an aliphatic aldehyde. Instead, aromatic aldehydes gave 5-substituted β-aminoketones or a single δ-diketone. The new compounds were characterized using spectroscopic methods and a single crystal structure analysis. Some of them showed anticancer and antibacterial properties.

Indexed as

antibacterialanticancer activitydihydropyridin-4(1H)-onestetrahydropyridinylidene salts

Identifiers

PMID37836712
PMCPMC10574582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.